Description
Fluclotizolam (Item No. 23524) is an analytical reference standard categorized as a thienotriazolodiazepine. This product is intended for research and forensic applications.
Chemical Properties
Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a triazolobenzodiazepine and is structurally similar to alprazolam. Flualprazolam is composed of a benzene ring fused to a seven-membered 1,4- diazepine ring. Flualprazolam also contains a fused triazolo ring. A methyl (-CH3) group is attached at the 1-position, a 2- fluorophenyl ring is attached at the 6-position, and a chlorine is attached at the 8-position of the triazolobenzodiazepine structure. Flualprazolam has a molecular formula of C17H12ClFN4 and a molecular weight of 326.76 g/mol.
History
Fluclotizolam is a thienotriazolodiazepine derivative which was first synthesised in 1979, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in 2017.
Uses
Fluclotizolam is one of the New Psychoactive Substancces (NPS).
Side effects
Fluclotizolam produces a sedative-hypnotic effect, often causing drowsiness, muscle relaxation and slowed, sluggish reactions.
Regulatory Status
Flualprazolam is not currently controlled under the Controlled Substances Act. At the 2020 Commission on Narcotic Drugs Sixty-third session, the Commission decided to include flualprazolam in Schedule IV of the 1971 Convention on Psychotropic Substance.
https://www.deadiversion.usdoj.govhttps://www.federalregister.gov
References
1. Moosmann, B., and Auw?rter, V. New Psychoactive Substances. Handbook of Experimental Pharmacology. Designer benzodiazepines: Another class of new psychoactive substances 252, 383-410 (2018).
